Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 623939, 12 pages
http://dx.doi.org/10.1155/2015/623939
Research Article

Correlation of Serum Levels of Endostatin with Tumor Stage in Gastric Cancer: A Systematic Review and Meta-Analysis

1Department of Tumor, The First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, China
2Department of Thoracic Surgery, The First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, China

Received 23 June 2014; Revised 25 November 2014; Accepted 13 December 2014

Academic Editor: Atsushi Sakuraba

Copyright © 2015 Zheng-Hua Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Yasui, K. Sentani, N. Sakamoto, K. Anami, Y. Naito, and N. Oue, “Molecular pathology of gastric cancer: research and practice,” Pathology Research and Practice, vol. 207, no. 10, pp. 608–612, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. R. Singh, “Gastric cancer stem cells: a novel therapeutic target,” Cancer Letters, vol. 338, no. 1, pp. 110–119, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. Ferro, B. Peleteiro, M. Malvezzi et al., “Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype,” European Journal of Cancer, vol. 50, no. 7, pp. 1330–1344, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. L. Dominguez, S. D. Crockett, J. L. Lund et al., “Gastric cancer incidence estimation in a resource-limited nation: use of endoscopy registry methodology,” Cancer Causes and Control, vol. 24, no. 2, pp. 233–239, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. Y.-S. Lee, Y. S. Cho, G. K. Lee et al., “Genomic profile analysis of diffuse-type gastric cancers,” Genome Biology, vol. 15, no. 4, article R55, 2014. View at Publisher · View at Google Scholar · View at PubMed
  6. J. Kim, Y. A. Cho, I. J. Choi et al., “Effects of polymorphisms of innate immunity genes and environmental factors on the risk of noncardia gastric cancer,” Cancer Research and Treatment, vol. 45, no. 4, pp. 313–324, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. Montori, F. Coccolini, M. Ceresoli et al., “The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art,” International Journal of Surgical Oncology, vol. 2014, Article ID 912418, 7 pages, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. H.-T. Arkenau, “Gastric cancer in the era of molecularly targeted agents: current drug development strategies,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 7, pp. 855–866, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. X.-C. Nie, J.-P. Wang, W. Zhu et al., “COL4A3 expression correlates with pathogenesis, pathologic behaviors, and prognosis of gastric carcinomas,” Human Pathology, vol. 44, no. 1, pp. 77–86, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. W. Masiak, A. Szponar, G. Chodorowska, A. Da̧browski, T. Pedowski, and G. Wallner, “Evaluation of endostatin and EGF serum levels in patients with gastric cancer,” Polish Journal of Surgery, vol. 83, no. 1, pp. 42–47, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. W. Zhuo, Y. Chen, X. Song, and Y. Luo, “Endostatin specifically targets both tumor blood vessels and lymphatic vessels,” Frontiers of Medicine in China, vol. 5, no. 4, pp. 336–340, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. W.-G. Jiang, X.-A. Lu, B.-Y. Shang et al., “Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis,” BMC Cancer, vol. 13, article 479, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. Y.-Y. Wan, G.-Y. Tian, H.-S. Guo et al., “Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats,” Respiratory Research, vol. 14, article 56, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. W. Zhuo, C. Luo, X. Wang, X. Song, Y. Fu, and Y. Luo, “Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells,” The Journal of Pathology, vol. 222, no. 3, pp. 249–260, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. X. Dong, X. Zhao, T. Xiao, H. Tian, and C. Yun, “Endostar, a recombined humanized endostatin, inhibits lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenograft in Mice,” Thoracic and Cardiovascular Surgeon, vol. 59, no. 3, pp. 133–136, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. Y.-J. Bai, L.-Z. Huang, A.-Y. Zhou, M. Zhao, W.-Z. Yu, and X.-X. Li, “Antiangiogenesis effects of endostatin in retinal neovascularization,” Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 7, pp. 619–626, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. H.-Y. Mo, D.-H. Luo, H.-Z. Qiu et al., “Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma,” Clinical Oncology, vol. 25, no. 5, pp. 308–317, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Q. Ni, H. Ji, Z. Zhao, X. Fan, and C. Xu, “Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism,” European Journal of Pharmacology, vol. 614, no. 1, pp. 1–6, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. L.-X. Li, Y.-L. Zhang, L. Zhou et al., “Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells,” Journal of Translational Medicine, vol. 11, article 257, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. T. Fujita, N. Gotohda, Y. Kato et al., “Clinicopathological features of stomach cancer with invasive micropapillary component,” Gastric Cancer, vol. 15, no. 2, pp. 179–187, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. G. Lurje, H. Husain, D. G. Power et al., “Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma,” Annals of Oncology, vol. 21, no. 1, Article ID mdp280, pp. 78–86, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. I. S. Woo, K.-A. Kim, H.-M. Jeon et al., “Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma,” International Journal of Cancer, vol. 119, no. 12, pp. 2901–2906, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. X. F. Huang, J. B. Zhou, G. Du, X. H. Pan, and R. H. Xu, “Clinical significace of serum VEGF and endostatin combined detection in patients with gastric cancer,” Chinese Journal of Digestive Endoscopy, vol. 23, pp. 200–203, 2006. View at Google Scholar
  24. G. Li, L. H. Li, and Y. G. Song, “Expression of TP and ES in the patients with gastric cancer and its clinical significance,” Jilin Medical Journal, vol. 30, pp. 197–198, 2009. View at Google Scholar
  25. N. Panic, E. Leoncini, G. de Belvis, W. Ricciardi, and S. Boccia, “Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses,” PLoS ONE, vol. 8, Article ID e83138, 2013. View at Google Scholar
  26. S. B. Edge and C. C. Compton, “The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. Zintzaras and J. P. A. Ioannidis, “HEGESMA: genome search meta-analysis and heterogeneity testing,” Bioinformatics, vol. 21, no. 18, pp. 3672–3673, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. E. Zintzaras and J. P. A. Ioannidis, “Heterogeneity testing in meta-analysis of genome searches,” Genetic Epidemiology, vol. 28, no. 2, pp. 123–137, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. F. Song and S. Gilbody, “Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis,” British Medical Journal, vol. 316, no. 7129, p. 471, 1998. View at Google Scholar · View at Scopus
  31. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, “Comparison of two methods to detect publication bias in meta-analysis,” Journal of the American Medical Association, vol. 295, no. 6, pp. 676–680, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. H. H. Ding, “Clinical significace of serum VEGF and endostatin combined with pathological features in patients with gastric cancer,” Zhejiang Clinical Medical Journal, vol. 10, pp. 375–376, 2008. View at Google Scholar
  33. Z. Li, H. Y. Zhang, S. F. Zai, B. D. Li, Z. B. Xie, and A. M. Yue, “Level and significance of vascular endothelial growth factor and endothelium colyone of gastric carcinoma,” Chinese Journal of Postgraduates of Medicine, vol. 30, pp. 36–37, 2007. View at Google Scholar
  34. F. G. Liu, H. M. Zhoiu, J. M. Xu, C. Y. Luan, Y. H. Zhang, and C. X. Zhao, “Relationships between serum levels of vascular endothelial growth factor and endostatin in patients with gastric carcinoma and clinical pathological characteristics,” Shandong Medical Journal, vol. 49, no. 25, pp. 11–13, 2009. View at Google Scholar
  35. S. Wang, X. Huang, X. H. Xu, and W. H. Chen, “Relation of serum endostatin levels with clinicopathologic characteristics and prognosis of gastric carcinoma,” Journal of Practical Oncology, vol. 21, pp. 549–551, 2006. View at Google Scholar
  36. S. D. Wang, “Clinical significace of serum MMP-9, VEGF and endostatin combined detection in patients with gastric cancer,” Shandong Medical Journal, vol. 51, pp. 67–68, 2011. View at Google Scholar
  37. Y. E. Yang, Q. S. Meng, and X. J. Sun, “Clinical significace of serum CEACA724VEGF and endostatin combined detection in patients with gastric cancer,” Medical Laboratory Science and Clinics, vol. 21, no. 6, pp. 67–69, 2010. View at Google Scholar
  38. H. Z. Yuan, C. Lv, X. W. Huang, and C. He, “Serum levels of vascular endothelial growth factor and endostatin in patients with gastric cancer and their clinical significance,” The Journal of Practical Medicine, vol. 26, pp. 586–587, 2010. View at Google Scholar
  39. M. Koç, E. Göçmen, M. Kiliç, M. Özbay, M. Öktem, and M. Tez, “Serum endostatin levels in gastric cancer patients: correlation with clinicopathological parameters,” Hepato-Gastroenterology, vol. 53, no. 70, pp. 616–618, 2006. View at Google Scholar · View at Scopus
  40. B. Ren, N. Höti, X. Rabasseda, Y.-Z. Wang, and M. Wu, “The antiangiogenic and therapeutic implications of endostatin,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 25, no. 3, pp. 215–224, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Folkman, “Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action,” Experimental Cell Research, vol. 312, no. 5, pp. 594–607, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. R. Xu, N. Ma, F. Wang et al., “Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer,” OncoTargets and Therapy, vol. 6, pp. 925–929, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. T.-H. Hu, C.-C. Huang, C.-L. Wu et al., “Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma,” Modern Pathology, vol. 18, no. 5, pp. 663–672, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus